From the start of my journey, Kristis depth of knowledge, kindness, and genuine care made all the difference
Serious adverse events were reported more in the semaglutide group than in the placebo group
More commonly, people quote the Lancet Diabetes & Endocrinology paper stating that the proportion of lean mass loss relative to total weight loss was similar to other obesity treatments, and that these findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide But other obesity treatments is vague
Studies in elderly populations, who share some constipation mechanisms with GLP-1 users (slower transit, reduced food intake), showed significant improvements in bowel movement frequency
Someone spending $40 a month on patches instead of consulting a healthcare provider about evidence-based options is losing time during which effective treatment could be producing results
(OUP Academic) Maurer AH